W1020

W146 hydrate

≥98% (HPLC)

• Synonim(y): ML056, R-3-amino-4-(3-hexylphenylamino)-4-oxobutylphosphonic acid hydrate, [(3R)-3-amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid
• Wzór empiryczny (zapis Hilla): C₁₆H₂₇N₂O₄P · xH₂O
• Numer CAS: 909725-61-7
• Masa cząsteczkowa: 342.37 (anhydrous basis)
• NACRES: NA.77
• PubChem Substance ID: 329830425
• UNSPSC Code: 12352211
• MDL number: MFCD16875441
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: off-white
• solubility: methanol: soluble (with 0.1% TFA)
• originator: Novartis
• storage temp.: 2-8°C
• SMILES string: O.CCCCCCc1cccc(NC(=O)[C@H](N)CCP(O)(O)=O)c1
• InChI: 1S/C16H27N2O4P.H2O/c1-2-3-4-5-7-13-8-6-9-14(12-13)18-16(19)15(17)10-11-23(20,21)22;/h6,8-9,12,15H,2-5,7,10-11,17H2,1H3,(H,18,19)(H2,20,21,22);1H2/t15-;/m1./s1
• InChI key: DQKSZHVSROOTFY-XFULWGLBSA-N

Opis

General description

W146 hydrate functions as an orthosteric antagonist. It is associated with blood lymphopenia and lung edema in mice.

Application

W146 hydrate has been used to assess vascular permeability in mice.

Biochem/physiol Actions

Potent S1P(1) competitive antagonist; Ki = 10-77 nM.

Features and Benefits

This compound is featured on the Lysophospholipid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable